LAMP Assay: Could it be a Boon for the Molecular Diagnosis of COVID-19?
- PDF / 157,190 Bytes
- 2 Pages / 595.276 x 790.866 pts Page_size
- 46 Downloads / 213 Views
LETTER TO THE EDITOR
LAMP Assay: Could it be a Boon for the Molecular Diagnosis of COVID-19? P. Buella Parivallal1,2 • M. K. Prasanna Kumar3 • K. C. Vasanthakumar1 Fathima F. Thavuroollah1 • Yamuna Manoharan1 • Sundaram Muthu1
•
Received: 2 July 2020 / Accepted: 8 July 2020 Ó Association of Clinical Biochemists of India 2020
Keywords LAMP assay COVID-19 RT-PCR Isothermal amplification Low cost Dear Editor, Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) has become a major threat for mankind and poses a great challenge to global economy. On 31st December 2019, the World Health Organization (WHO) was informed about a cluster of pneumonia cases in Wuhan, China [1]. Subsequent investigations identified a completely unique sequence of coronavirus which differed from existing type SARS-CoV known as SARS-CoV-2. Initially, it was observed within the Wuhan province of China but later spread fast to rest of the world, which forced WHO to declare COVID-19 as pandemic. So far there is a total of 10,302,867 confirmed cases, with 505,518 global deaths, while 5,558,161 are recovered cases. In India, a total of 5,68,473 confirmed cases out of which 2,15,838 of active cases and 3,35,656 of recovered cases also 16,919 of the death cases are reported till date. The SARS-CoV-2 is a single-stranded, positive-sense RNA
P. Buella Parivallal and K. C. Vasanthakumar have contributed equally to this work. & Sundaram Muthu [email protected]; [email protected] 1
Winomicx Molecular Diagnostics and Research Pvt Ltd, Golden Jubilee Biotech Park for Women Society, Inside Sipcot IT Park, Siruseri, Chennai 603 103, India
2
Dendrite Laboratories Pvt Ltd, Judicial Layout Yelahanka, Bangalore 560065, India
3
Department of Plant Pathology, University of Agricultural Sciences, Bangalore 560065, India
virus [2] with its complete genetic sequence been decoded and made available to the Global Initiative on Sharing All Influenza Data (GISAID) platform on January 10, 2020. This provided an opportunity for several R&D companies and research institutes to design specific primers targeting COVID-19 which further lead to the development of RTPCR diagnostic kits (NCBI Reference Sequence: NC_045512.2). Currently there is search for the development of highly sensitive and specific molecular diagnostic kits in line with real time PCR (RT-PCR), easy to use and cost-effective which is vital in combating the evolving SARS-CoV-2 pandemic. Timely identification of individuals infected with SARS-CoV-2 will enable rapid isolation of infected patients and track their contacts to screen and also to prevent further spread of the virus. Till date, the majority of molecular diagnostic test kits have utilized the RT-PCR technology targeting different genomic regions of SARSCoV-2 for detection in line with other serological techniques for aiding the accurate diagnosis of infection [3]. PCR-based methods can detect very low levels of viral RNA, so are highly sensitive and can enable early diagnosis of COVID-19 within few days of infection. How
Data Loading...
